Affiliation:
1. Moscow City Oncological Hospital No.1, Moscow Healthcare Department
2. Moscow Healthcare Department
Abstract
Introduction. Genetic testing has become the part of the practice of providing specialized cancer care. This allows not only detecting the further tactics for patient management, but also identifying a risk group for the occurrence of malignant neoplasms (MNP). However, there are still no algorithms for dispensary monitoring of healthy carriers of mutations, which determined the relevance of our study.
The purpose of the study was to propose an organizational model for the work of the office of hereditary tumor pathology (HTP) based on the analysis of our own experience in identifying patients with hereditary oncological syndromes and their relatives as potent carriers of mutations associated with an increased risk of occurring MNP.
Materials and methods. Genetic testing was carried out in two thousand two hundred seventy six patients (residents of Moscow) with breast, gastrointestinal tract, and ovarian cancer.
Results. 714 patients out of 2276 MNP patients had mutations associated with an increased risk of developing cancer. Further, 277 relatives of these patients were invited, and mutations were detected in 143 (51.7%). Based on these data, an management model of the HTP office was proposed as part of the Outpatient Oncology Center (OOC), and the need for specialists to work in the HTP office per 100 thousand people was determined —
0.06 oncologist’s rate, 0.03 doctor’s rate-genetics and 0.03 psychologist rates.
Limitations. This study did not include patients who did not meet the selection criteria, as well as persons under 18 years of age or who isn’t resident of Moscow.
Conclusion. The introduction of genetic testing of patients’ relatives into practice will allow forming risk groups for subsequent dispensary observation, early detection of tumor and precancerous pathology.
Publisher
Federal Scientific Center for Hygiene F.F.Erisman
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference15 articles.
1. Baranova E.E., Bodunova N.A., Vorontsova M.V., Zakharova G.S., Makarova M.V., Rumyantsev P.O. Hereditary cancer syndromes: a modern paradigm. Problemy endokrinologii. 2020; 66(4): 24–34. https://doi.org/10.14341/probl12366 https://elibrary.ru/sxayzn (in Russian)
2. Wilson J.M.G., Jungner G. Principles and Practice of Screening for Disease. Geneva; 1968.
3. Sultanbaev A.V., Nasretdinov A.F., Galeev M.G., Men’shikov K.V., Musin Sh.I., Sultanbaeva N.I., et al. Breast cancer screening in germline mutation carriers. A literature review. Opukholi zhenskoy reproduktivnoy sistemy. 2023; 19(2): 16–24. https://doi.org/10.17650/1994-4098-2023-19-2-16-24 (in Russian)
4. Semenova A.B., Byakhova M.M., Galkin V.N., Parts S.A., Makarova M.V., Nemtsova M.V., et al. Capabilities of molecular genetic methods for effective hereditary cancers detection in individuals with high cancer risk factors. Zdorov’e megapolisa. 2023; 4(2): 30–40. https://clck.ru/37BCRC https://elibrary.ru/kvcmae (in Russian)
5. Kaprin A.D., Starinskiy V.V., Shakhzadova G.V. Malignant Neoplasms in Russia in 2021 (Morbidity and Mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’)]. Moscow; 2022. (in Russian)